PERSERIS KIT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Perseris Kit, and what generic alternatives are available?
Perseris Kit is a drug marketed by Indivior and is included in one NDA. There are ten patents protecting this drug.
This drug has thirty-eight patent family members in seventeen countries.
The generic ingredient in PERSERIS KIT is risperidone. There are thirty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the risperidone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Perseris Kit
A generic version of PERSERIS KIT was approved as risperidone by APOTEX INC on September 15th, 2008.
Summary for PERSERIS KIT
International Patents: | 38 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 143 |
Clinical Trials: | 1 |
Patent Applications: | 3,982 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PERSERIS KIT |
DailyMed Link: | PERSERIS KIT at DailyMed |
Recent Clinical Trials for PERSERIS KIT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Indivior Inc. | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for PERSERIS KIT
US Patents and Regulatory Information for PERSERIS KIT
PERSERIS KIT is protected by ten US patents.
Patents protecting PERSERIS KIT
Sustained delivery formulations of risperidone compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Sustained release small molecule drug formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADMINISTRATION OF RISPERIDONE
Sustained delivery formulations of risperidone compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING SCHIZOPHRENIA
Sustained release small molecule drug formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING SCHIZOPHRENIA
Sustained delivery formulations of risperidone compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SCHIZOPHRENIA
Sustained release small molecule drug formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SCHIZOPHRENIA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SCHIZOPHRENIA
Sustained delivery formulations of risperidone compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Sustained delivery formulations of risperidone compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SCHIZOPHRENIA
Sustained release small molecule drug formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indivior | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Indivior | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-002 | Jul 27, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Indivior | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Indivior | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for PERSERIS KIT
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Laboratorios Farmacéuticos Rovi, S.A. | Okedi | risperidone | EMEA/H/C/005406 Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. |
Authorised | no | no | no | 2022-02-14 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for PERSERIS KIT
See the table below for patents covering PERSERIS KIT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 101365423 | Sustained release small molecule drug formulation | ⤷ Sign Up |
Japan | 2009510116 | ⤷ Sign Up | |
Spain | 2562878 | ⤷ Sign Up | |
Hong Kong | 1143731 | 利培酮類化合物的緩釋製劑 (SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUNDS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PERSERIS KIT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0196132 | 94C0008 | Belgium | ⤷ Sign Up | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |